Skip to main content
. 2019 Jun 30;3(Suppl):28-30. doi: 10.1097/HS9.0000000000000244

Figure 1.

Figure 1

Mechanisms of action for CTLA-4 and PD-1. (A) CTLA-4 acts at the priming phase of the immune response enhancing the activation of T lymphocytes. (B) The main anatomical site of PD-1 activity is the tumor microenvironment. Monoclonal antibodies targeting PD-1/PD-L1 normalize the antitumor immune response. This figure contains elements from Servier Medical Art.